Key clinical point: Early wearing-off effect (WOE) is common in patients with chronic migraine (CM) receiving onabotulinumtoxinA (OnabotA) and more frequent after the first cycle of OnabotA, with depression and anxiety disorders being clinical predictors of the WOE.
Major finding: Early WOE was reported more frequently after the first vs second treatment cycle of OnabotA (35.6% vs 23.8% of patients), with depression and anxiety disorders being significant clinical predictors of WOE (odds ratio 3.4; 95% CI 1.22-10.84; P = .028).
Study details: Findings are from a prospective real-life study including 59 patients with CM and insufficient response, absence of tolerability, or contraindications to previous migraine therapies who initiated prophylactic treatment with OnabotA, 40.6% of whom reported a WOE.
Disclosures: This study received no external funding. The authors declared no conflicts of interest.
Source: Rodríguez-Montolio J et al. Early wearing-off effect of OnabotulinumtoxinA in chronic migraine: A prospective real-life study. J Clin Med. 2023;12(16):5360 (Aug 17). doi: 10.3390/jcm12165360